我们无缘无故地做的事情TM:避免纳尔特雷克松用于肝脏疾病中的酒精使用障碍
Dustin P Kee1, John J Buyske1, Susan L Calcaterra2
1Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Journal of hospital medicine
|December 10, 2024
概括
由于酒精使用障碍 (AUD) 的住院治疗是频繁的,但药物治疗未得到充分利用. 纳尔特雷克松是安全有效的减少酒精消费和防止再入院,即使在肝硬化患者.
科学领域:
- * 内部医学 内部医学
- * 药物成 药物成 医学
- * 药理学 药理学 药理学
背景情况:
- * 酒精使用障碍 (AUD) 经常导致住院治疗,但指导方针推的药物治疗未得到充分使用.
- *用于AUD的药物纳尔特雷已经证明了安全性和有效性,即使在肝硬化患者中,也消除了对肝毒性的先前担忧.
- * 关于纳尔特雷的益处的处方知识差距阻碍了其在临床实践中的采用.
研究的目的:
- *为了突出纳尔特雷在治疗酒精使用障碍 (AUD) 的不足,尽管它已被证明是有效和安全的.
- *强调医院环境是启动纳尔特雷克松治疗的关键机会.
- * 鼓励医院医生克服障碍,并为AUD管理处方纳尔特雷.
主要方法:
- *对纳尔特雷在治疗酒精使用障碍 (AUD) 的疗效和安全性现有文献的综述.
- *分析当前临床实践模式关于医院住院期间AUD的药物治疗.
- * 讨论纳尔特雷在减少重度酒精消费和预防不良健康后果方面的益处.
主要成果:
- * 纳尔特雷克松已被证明有效降低重度酒精消费,并且即使对于肝硬化患者来说也是安全的.
- *缺乏处方医生的意识是纳尔特雷在治疗酒精使用障碍 (AUD) 中使用的重要障碍.
- *住院治疗提供了一个启动纳尔特雷克森的关键机会,可能减少再入院和肝病进展.
结论:
- *医院医生应积极考虑并为患有酒精使用障碍 (AUD) 的患者开处方纳尔德.
- * 解决处方医生的知识差距对于增加纳尔特雷克森吸收至关重要.
- *在住院期间及时开始使用纳尔特雷可以改善患者的治疗结果,并减少医疗保健利用率.
相关概念视频
CNS Depressants: Alcohol and Nicotine
181
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
181
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drug Dependence
989
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
989
Diseases of the Liver and Gallbladder
486
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
486
Hepatic Drug Excretion: Enterohepatic Cycling
1.4K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.4K


